Searchable abstracts of presentations at key conferences in endocrinology

ea0050ep051 | Clinical Biochemistry | SFEBES2017

Primum Non Nocere – the need for appropriate assessment before starting testosterone therapy

Moriarty Maura , Meeran Karim , George Emad

A 41 year old Emirati man was reviewed in January 2016 for hypercholesterolaemia managed on diet alone, but direct questioning revealed gradual onset erectile dysfunction over 2 years, treated by a urologist elsewhere. Initial response to Cialis had waned over 18 months. Testosterone replacement (Nebido) had been initiated in June 2015 on the basis of one low morning total testosterone of 3.89 nmol/L (normal range 8.64 – 29). SHBG and prolactin...

ea0050ep051 | Clinical Biochemistry | SFEBES2017

Primum Non Nocere – the need for appropriate assessment before starting testosterone therapy

Moriarty Maura , Meeran Karim , George Emad

A 41 year old Emirati man was reviewed in January 2016 for hypercholesterolaemia managed on diet alone, but direct questioning revealed gradual onset erectile dysfunction over 2 years, treated by a urologist elsewhere. Initial response to Cialis had waned over 18 months. Testosterone replacement (Nebido) had been initiated in June 2015 on the basis of one low morning total testosterone of 3.89 nmol/L (normal range 8.64 – 29). SHBG and prolactin...

ea0086p188 | Bone and Calcium | SFEBES2022

Severe symptomatic and treatment resistant hypercalcaemia caused by a parathyroid adenoma

Javid Pernia , Lam George , Kurera Isuri

A 74 year-old woman had 4 presentations to the hospital with severe symptomatic hypercalcemia despite intensive medical therapy. She had a background of right hemithyroidectomy, hypothyroidism and rheumatoid arthritis. She first presented with symptoms of muscle weakness, vomiting, confusion and muscle aches. Her initial test results showed an adjusted calcium level of 3.79 mmol/l and PTH of 28.1 pmol/l; she was treated with IV fluids, Pamidronate 60 mg and discharged home wit...

ea0086p118 | Reproductive Endocrinology | SFEBES2022

Determining the impact of FSH glycosylation variants on the pre-antral follicle transcriptome in the ageing ovary

Johnson Gillian , Bousfield George , Jonas Kim

Ovarian ageing is a naturally occurring physiological process, marked by dynamic changes in ovarian function and hormone secretion. A key of ovarian regulator is follicle stimulating hormone (FSH). FSH is secreted as two glycosylation variants: partially glycosylated FSH (FSH21) and fully glycosylated FSH (FSH24). Analysis has shown that the ratio of FSH21:FSH24 changes with age, with FSH21 predominant during reproductive prime, and FSH24 predominant around menopause. How FSH ...

ea0090p553 | Adrenal and Cardiovascular Endocrinology | ECE2023

Cushingoid features in a patient with adrenal insufficiency secondary to combined inhaled steroid and Itraconazole therapy

Nagarajah Kalyani , George Lindsay , Lansdown Andrew

Background: Iatrogenic adrenal insufficiency (AI) refers to primary, secondary, or tertiary hypoadrenalism associated with drug administration, surgery, or irradiation. The most common cause of secondary adrenal insufficiency is exogenous glucocorticoids. Hepatic metabolism of inhaled corticosteroids (ICS) takes place via cytochrome P450 3A4. Nevertheless, it can be decreased by enzyme inhibitors such as itraconazole or ritonavir, thus leading to an increase in the bioavailabi...

ea0065p357 | Reproductive Endocrinology and Biology | SFEBES2019

Deciphering the effects of testosterone on FSH glycosylation variant-dependent ERK/MAPK activation

Kellaway Jedidiah , Bousfield George , Jonas Kim

The heterodimeric glycoprotein hormone, follicle stimulating hormone (FSH) and its receptor (FSHR) are vital for reproductive function, driving ovarian function via follicular recruitment, selection and development. FSH exists as two predominant glycoforms in females; partially glycosylated (FSH21) and fully glycosylated (FSH24), based on differing glycosylation patterns of the β subunit. The FSH glycoforms have different bioactivities, with FSH21 displaying a higher bind...

ea0065p369 | Reproductive Endocrinology and Biology | SFEBES2019

Investigating placental endocrine dysfunction in a translationally relevant mouse model of fetal growth restriction

Bertlin James , George Roberts , Tunster Simon

Fetal growth restriction (FGR), which describes the failure of a fetus to achieve its genetic growth potential, not only increases the risk of perinatal mortality and morbidity but also predisposes to metabolic disease in adulthood. In developed countries, FGR is typically attributed to dysfunction of the placenta – a transient organ that mediates nutrient supply, eliminates waste, and protects the fetus from maternal immune response. The placenta also functions as a majo...

ea0063p5 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

Paraganglioma of the urinary bladder wall: 2 cases with 2 different presentations

Salloum Cynthia , Sawan Carla , Assaf George

Objective: We present two cases of patients with Paraganglioma of the urinary bladder wall, illustrating the differences in diagnosis and management.Case 1: An 80-year-old female known to have diabetes and hyperthyroidism (treated) presented to her urologist with painless hematuria. Cystoscopy was done and bladder polyps were biopsied. Results of the tumors sampled showed paraganglioma of the urinary bladder wall, although patient was asymptomatic. She p...

ea0041gp8 | Adrenal | ECE2016

Adequate salt intake attenuates mineralocorticoid receptor antagonist-induced hyperkalemia in patients with primary aldosteronism

Fountoulakis Stelios , Papanastasiou Labrini , Piaditis George

Introduction: Mild hyperkalemia is a common side-effect of mineralocorticoid receptor antagonists (MRA), which can be precipitated by minimizing dietary salt intake. Restoration of salt intake can overcome diminished kaliuresis and restore potassium levels. Aim of this study was the evaluation of the effect of adequate salt consumption on plasma potassium levels in relation to the mean, maximum and minimum blood pressure (BP) in MRA-treated sodium-depleted hyperkalemic patient...

ea0059p139 | Neuroendocrinology and pituitary | SFEBES2018

Postoperative metabolic profile of patients after pituitary surgery

Rajaratnam Simon , Jeyaseelan Lakshmanan , Chacko Ari George

Objective: To study the metabolic profile of patients after surgery for pituitary tumors.Methods: This retrospective study included 1138 patients from 2000 to 2017. Those with prolactinomas, pituitary apoplexy and surgery elsewhere were excluded. The analysis included 525 patients, non-functional tumors (143), acromegaly (267), Cushing’s disease (113) and TSHoma (1). The patients’ blood pressure, blood sugar, lipid profile and body mass index (...